A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

医学 恶心 内科学 不利影响 胃肠病学 实体瘤疗效评价标准 酪氨酸激酶抑制剂 肺癌 队列 免疫组织化学 肿瘤科 呕吐 便秘 癌症 进行性疾病 化疗
作者
Eric Angevin,Gianluca Spitaleri,Jordi Rodón,Katia Dotti,Nicolás Isambert,Stefania Salvagni,Víctor Moreno,Sylvie Assadourian,Corinne Gomez,Marzia Harnois,Antoine Hollebecque,Analía Azaro,Alice Hervieu,Karim Rihawi,Filippo de Marinis
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:87: 131-139 被引量:37
标识
DOI:10.1016/j.ejca.2017.10.016
摘要

PurposeDysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was investigated in patients with advanced solid tumours and MET dysregulation.MethodsThis was a phase I dose-escalation (3 + 3 design [50–740 mg/m2]) and dose-expansion study. In the dose escalation, patients had high total MET (t-MET) expression by immunohistochemistry (IHC) or MET amplification by fluorescence in situ hybridisation. In the dose expansion, patients had MET amplification (including a subset of patients with non-small cell lung cancer [NSCLC]) or phosphorylated-MET (p-MET) expression (IHC). Objectives were determination of maximum tolerated dose (MTD) of once-weekly intravenous SAR125844 based on dose-limiting toxicities; safety and pharmacokinetic profile; preliminary efficacy of SAR125844 MTD in the expansion cohort.ResultsIn total, 72 patients were enrolled: dose escalation, N = 33; dose expansion, N = 39; 570 mg/m2 was established as the MTD. Most frequent treatment-emergent adverse events (AEs) were asthenia/fatigue (58.3%), nausea (31.9%), and abdominal pain, constipation, and dyspnea (27.8% for each); 58.3% of patients reported grade 3 AEs (19.4% were treatment related). Of the 29 evaluable patients with MET amplification treated at 570 mg/m2, five achieved a partial response, including four of 22 with NSCLC; 17 patients had stable disease. No response was observed in patients with high p-MET solid tumours. There was no correlation between tumour response and t-MET status or MET gene copy number.ConclusionThe MTD of once-weekly SAR125844 was 570 mg/m2; SAR125844 was well tolerated, with significant antitumour activity in patients with MET-amplified NSCLC.Clinical trial registration number: NCT01391533
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
juliar完成签到 ,获得积分10
5秒前
Akim应助DeepLearning采纳,获得10
9秒前
迈克老狼完成签到 ,获得积分10
10秒前
Kelevator完成签到,获得积分10
15秒前
DeepLearning完成签到,获得积分20
16秒前
19秒前
DeepLearning发布了新的文献求助10
22秒前
SOL完成签到 ,获得积分10
37秒前
丝丢皮的完成签到 ,获得积分10
40秒前
t铁核桃1985完成签到 ,获得积分10
40秒前
丝丢皮得完成签到 ,获得积分10
46秒前
爆米花应助DeepLearning采纳,获得10
50秒前
铜豌豆完成签到 ,获得积分10
50秒前
cheng完成签到,获得积分10
57秒前
君看一叶舟完成签到 ,获得积分10
1分钟前
在水一方应助科研通管家采纳,获得10
1分钟前
1分钟前
Chuang完成签到 ,获得积分10
1分钟前
热心市民完成签到 ,获得积分10
1分钟前
吃不胖的魔芋丝完成签到 ,获得积分10
1分钟前
1分钟前
李东东完成签到 ,获得积分10
1分钟前
fsznc1完成签到 ,获得积分0
1分钟前
年轻的笙完成签到,获得积分10
1分钟前
嘻嘻完成签到 ,获得积分10
1分钟前
huiluowork完成签到 ,获得积分10
1分钟前
1分钟前
拾陆发布了新的文献求助10
1分钟前
乔杰完成签到 ,获得积分10
1分钟前
ramsey33完成签到 ,获得积分10
1分钟前
小静完成签到 ,获得积分10
1分钟前
默笙完成签到 ,获得积分10
1分钟前
小乙猪完成签到 ,获得积分0
2分钟前
赵帅完成签到 ,获得积分10
2分钟前
2分钟前
西扬完成签到 ,获得积分10
2分钟前
2分钟前
Ray完成签到 ,获得积分10
2分钟前
yyds完成签到,获得积分10
2分钟前
DeepLearning发布了新的文献求助10
2分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990835
求助须知:如何正确求助?哪些是违规求助? 3532241
关于积分的说明 11256614
捐赠科研通 3271100
什么是DOI,文献DOI怎么找? 1805229
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809236